Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

EP: 1.Value of Comprehensive Molecular Testing in NSCLC

EP: 2.Unmet Needs in HER2-Mutant NSCLC

EP: 3.Treatment of HER2-Mutant NSCLC: Consequences of Delays and Strategies to Improve Timely Initiation

EP: 4.Overview of HER2-Targeted Therapies in NSCLC

EP: 5.Mechanistic Role of Emerging Tyrosine Kinase Inhibitors (TKIs) in HER2-Mutant NSCLC

EP: 6.Efficacy and Safety of Zongertinib in Previously Treated and Treatment-Naïve HER2-Mutant NSCLC from Beamion LUNG-1 Trial

EP: 7.Evaluating TKI Efficacy and Safety in HER2-Mutant NSCLC from SOHO-01 Trial

EP: 8.Safety Considerations and Patient-Reported Outcomes of TKIs in HER2-Mutant NSCLC

EP: 9.Opportunities for Positioning TKIs as First-Line Therapy in HER2-Mutant NSCLC

EP: 10.Additional Emerging HER2-Targeted Therapies in NSCLC

EP: 11.Strategies for Evaluating NSCLC Therapies Granted FDA Accelerated Approval

Now Viewing

EP: 12.Addressing Access Barriers for HER2-Targeted Therapies in NSCLC

This episode examines the barriers to accessing HER2-targeted therapies for non-small cell lung cancer (NSCLC) and strategies to overcome them. The discussion highlights the importance of aligning with payer requirements and clinical guidelines, such as those from NCCN, to facilitate insurance approval of recently FDA-approved HER2-targeted treatments. Panelists address practical challenges, including differences in the approval process for oral versus infusion therapies, the need for prior authorizations, and frequent initial insurance denials. They emphasize the crucial role of pharmacy teams, specialty pharmacies, and patient assistance programs in supporting patients through the approval process and helping to manage treatment costs. The conversation underscores the persistence sometimes required to secure coverage and the value of team-based approaches, including working with pharmacy liaisons and advocacy resources. Ultimately, practices are encouraged to become familiar with access pathways and available support mechanisms to ensure eligible patients receive timely and appropriate HER2-targeted therapies.